Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion

Key Points

• To assess risk stratification in patients with residual triple-negative breast cancer after neoadjuvant therapy.
• Analyzed residual cancer burden and lymphovascular invasion in patients.
• Stratified patients into risk groups based on these factors.
• Evaluated the variability of adjuvant treatment effects across risk groups.
• Patients with different residual cancer burden classes showed varied responses to adjuvant treatments.
• Lymphovascular invasion presence further refined these risk stratifications.
• Tailored adjuvant treatment based on RCB and LVI may improve patient outcomes.